Skip Navigation



Carcinogenesis Advance Access published online on January 19, 2008

Carcinogenesis, doi:10.1093/carcin/bgn010
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
29/3/560    most recent
bgn010v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cucciolla, V.
Right arrow Articles by Della Ragione, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cucciolla, V.
Right arrow Articles by Della Ragione, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Histone deacetylase inhibitors up-regulate p57Kip2 level by enhancing its expression through Sp1 transcription factor

Valeria Cucciolla1, Adriana Borriello1, Maria Criscuolo1, Antonio A. Sinisi2, Debora Bencivenga1, Annunziata Tramontano1, Anna Chiara Scudieri1, Adriana Oliva1, Vincenzo Zappia1 and Fulvio Della Ragione1,3

1 Department of Biochemistry and Biophysics «F. Cedrangolo», Second University of Naples, Italy, and
2 Istituto di Endocrinologia, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Second University of Naples, Italy

3. To whom all the correspondence should be addressed:Dr. Fulvio Della Ragione, Department of Biochemistry and Biophysics «F. Cedrangolo», Second University of Naples, Via Costantinopoli, 16, 80138, Naples, Italy. Phone +39-081-5665812. Fax +39-081-5665812. E.mail fulvio.dellaragione{at}unina2.it.

Histone deacetylase inhibitors (HDACIs) represent a new class of targeted anticancer agents. Here, we evaluate the effects of butyrate (BuA) and other HDACIs on p57Kip2, a cyclin-dependent kinase inhibitor (cki). We observed that inhibitors of class I/II HDACs, but not of class III HDACs, induce a remarkable accumulation of p57Kip2 in several cells. The cki up-regulation is associated with an increased gene expression that was not prevented by cycloheximide, indicating that HDACIs affect directly p57Kip2 transcription. The characterization of p57Kip2 promoter indicates that the first 165 bps are mostly involved in the BuA effects. Chromatin immunoprecipitation studies demonstrated that the BuA treatment causes the recruitment of Sp1 transcription factor. The Sp1 importance was confirmed by the reduction of BuA effects by mithramycin A (an Sp1 antagonist) and, most stringently, by Sp1 down-regulation due to Sp1 siRNA. Moreover, both the treatments reduce the p57Kip2 transcription in untreated cells, suggesting that Sp1 is required for the constitutive cki expression. Studies employing plasmids containing parts of the 165 bps of p57Kip2 promoter indicate that the promoter region between –87 and -113 bps, that includes two putative Sp1 consensus sequences, plays a critical role in the response to HDACIs. Since this p57Kip2 promoter region also embraces the consensus sequence for the transcriptional repressor CTIP2, we evaluated whether this factor is involved into the BuA effect. When CTIP2 was down-regulated by a specific siRNA, we observed the enhancement of BuA activity on p57Kip2 expression suggesting that CTIP2 might be also involved in HDACIs effects.

Key Words: histone deacetylase inhibitors • p57Kip2 • cell division cycle


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.